Аннотация:
At present, compelling evidence has been obtained that combined therapy of pulmonary arterial hypertension (PAH) with specific drugs can significantly slow progression of PAH. Therefore, in current guidelines combination therapy is already considered as standard treatment for a significant proportion of patients with moderately severe and severe forms of PAH. However, the quality of life and long-term prognosis of patients receiving combination therapy, should be the object of further research. The future research is absolutely necessary to identify the most optimal strategy of treatment of patients with PAH, such as initial combination therapy or rapid sequential combination therapy, double or triple combinations as well as exploring new signaling pathways PAH, which can become targets for new specific drugs PAH. © 2018 Media Sphera Publishing Group. All rights reserved.
Ключевые слова:
Combination therapy; Pulmonary arterial hypertension; Pulmonary hypertension; Specific therapy
antihypertensive agent; human; multimodality cancer therapy; pulmonary hypertension; quality of life; Antihypertensive Agents; Combined Modality Therapy; Humans; Hypertension, Pulmonary; Quality of Life
Авдеев С. Н. Сергей Николаевич 1968-
Царева Н. А. Наталья Анатольевна 1972-
Гаисин И. Р.
Avdeev S. N. Sergej Nikolaevich 1968-
Tsareva N. A. Natal`ya Anatolyevna 1972-
Gaisin I. R.
Combination therapy is a new standard for treatment of pulmonary arterial hypertension
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 90, Вып. 3 С. 72-80
2018
Статья
Combination therapy Pulmonary arterial hypertension Pulmonary hypertension Specific therapy
antihypertensive agent human multimodality cancer therapy pulmonary hypertension quality of life Antihypertensive Agents Combined Modality Therapy Humans Hypertension, Pulmonary Quality of Life
At present, compelling evidence has been obtained that combined therapy of pulmonary arterial hypertension (PAH) with specific drugs can significantly slow progression of PAH. Therefore, in current guidelines combination therapy is already considered as standard treatment for a significant proportion of patients with moderately severe and severe forms of PAH. However, the quality of life and long-term prognosis of patients receiving combination therapy, should be the object of further research. The future research is absolutely necessary to identify the most optimal strategy of treatment of patients with PAH, such as initial combination therapy or rapid sequential combination therapy, double or triple combinations as well as exploring new signaling pathways PAH, which can become targets for new specific drugs PAH. © 2018 Media Sphera Publishing Group. All rights reserved.